These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 28017969)

  • 1. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
    Krönke J; Kuchenbauer F; Kull M; Teleanu V; Bullinger L; Bunjes D; Greiner A; Kolmus S; Köpff S; Schreder M; Mügge LO; Straka C; Engelhardt M; Döhner H; Einsele H; Bassermann F; Bargou R; Knop S; Langer C
    Leukemia; 2017 Jun; 31(6):1363-1367. PubMed ID: 28017969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.
    Tachita T; Kinoshita S; Ri M; Aoki S; Asano A; Kanamori T; Yoshida T; Totani H; Ito A; Kusumoto S; Komatsu H; Yamagata K; Kubo K; Tohkin M; Fukuda S; Iida S
    Cancer Sci; 2020 Apr; 111(4):1333-1343. PubMed ID: 32061138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
    Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
    Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
    Krönke J; Udeshi ND; Narla A; Grauman P; Hurst SN; McConkey M; Svinkina T; Heckl D; Comer E; Li X; Ciarlo C; Hartman E; Munshi N; Schenone M; Schreiber SL; Carr SA; Ebert BL
    Science; 2014 Jan; 343(6168):301-5. PubMed ID: 24292625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
    Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
    Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
    Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
    Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
    Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
    Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide.
    Pourabdollah M; Bahmanyar M; Atenafu EG; Reece D; Hou J; Chang H
    J Hematol Oncol; 2016 Nov; 9(1):123. PubMed ID: 27881177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
    Huang SY; Lin CW; Lin HH; Yao M; Tang JL; Wu SJ; Chen YC; Lu HY; Hou HA; Chen CY; Chou WC; Tsay W; Chou SJ; Tien HF
    Ann Hematol; 2014 Aug; 93(8):1371-80. PubMed ID: 24687382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3.
    Liu XP; He L; Zhang QP; Zeng XT; Liu SQ
    Med Sci Monit; 2018 May; 24():2809-2817. PubMed ID: 29729093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
    Bolomsky A; Hübl W; Spada S; Müldür E; Schlangen K; Heintel D; Rocci A; Weißmann A; Fritz V; Willheim M; Zojer N; Palumbo A; Ludwig H
    Am J Hematol; 2017 Mar; 92(3):269-278. PubMed ID: 28052520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel mechanism of lenalidomide activity.
    Fink EC; Ebert BL
    Blood; 2015 Nov; 126(21):2366-9. PubMed ID: 26438514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
    Heintel D; Rocci A; Ludwig H; Bolomsky A; Caltagirone S; Schreder M; Pfeifer S; Gisslinger H; Zojer N; Jäger U; Palumbo A
    Br J Haematol; 2013 Jun; 161(5):695-700. PubMed ID: 23565715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
    Fuchs O
    Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
    Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
    Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular mechanism of thalidomide analogs in hematologic malignancies.
    Lindner S; Krönke J
    J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
    Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
    Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical significance of cereblon expression in multiple myeloma.
    Schuster SR; Kortuem KM; Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Ahmann G; Kumar S; Rajkumar SV; Mikhael J; Laplant B; Champion MD; Laumann K; Barlogie B; Fonseca R; Bergsagel PL; Lacy M; Stewart AK
    Leuk Res; 2014 Jan; 38(1):23-8. PubMed ID: 24129344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
    Petzold G; Fischer ES; Thomä NH
    Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.